Lahore: Abbott Laboratories (Pakistan) Limited has announced that its Board of Directors will convene virtually on Tuesday, October 27th, 2026, at 11:30 a.m. to review the company's quarterly accounts for the period ending September 30th, 2026. This meeting is part of the company's regular financial oversight process.

In accordance with the requirements set forth by the Pakistan Stock Exchange (PSX) under Clause 5.6.4 of its regulations, Abbott Laboratories has instituted a "Close Period" starting from October 20th, 2026, and extending through October 27th, 2026. During this period, which is standard for publicly listed companies, no director, CEO, or executive of the company is permitted to engage in any transactions involving the company's shares, either directly or indirectly.

The designated market category for Abbott Laboratories (Pakistan) Limited falls under the jurisdiction of the Pakistan Stock Exchange. According to information available from the Pakistan Stock Exchange (PSX), the adherence to such protocols ensures a fair trading environment and transparency in financial disclosures. The outcome of the upcoming board meeting and the quarterly financial results are anticipated by stakeholders for insights into the company's performance and strategic direction.

The implementation of the Close Period is crucial to maintaining compliance and preventing any potential conflicts of interest or insider trading scenarios. As the company prepares to disclose its financial performance, investors and market analysts will be closely monitoring the results for indications of Abbott Laboratories' operational efficacy and market positioning in the upcoming quarters.